肝细胞癌患者经免疫检查点抑制剂为基础的系统治疗达完全缓解后的结局与管理
这项回顾性多中心研究纳入3933例接受ICI为基础非根治性系统治疗的HCC患者,174例(4.4%)达CR-mRECIST,97例(2.5%)同时达CR-RECISTv1.1。中位随访32.2个月,1年和3年总生存率分别为98%和86%,仅CR-mRECIST和CR-RECISTv1.1患者无复发生存率均良好。首次mRECIST CR后接受免疫治疗≥6个月者无复发生存期长于更早停药者(p=0.008)。
要点
- HCC患者ICI为基础系统治疗后CR-mRECIST发生率为4.4%,CR-RECISTv1.1为2.5%。
- CR患者1年和3年总生存率分别为98%和86%,无复发生存率良好。
- 首次mRECIST CR后免疫治疗≥6个月者无复发生存期更长(p=0.008)。
核心结论
- 仅CR-mRECIST和CR-RECISTv1.1患者的总体生存和无复发生存均良好,9例接受根治性手术转化治疗者中8例(89%)获病理学CR。
- 尽管存在潜在局限性,这些发现支持在免疫治疗背景下使用mRECIST进行临床决策。
- 考虑停用ICI时,CR后继续治疗至少6个月似乎是可取的。
研究设计与样本
- 回顾性研究,纳入亚洲、欧洲和美国28个中心中接受ICI为基础系统治疗并按mRECIST达CR的HCC患者。
- 3933例接受ICI为基础非根治性系统治疗的HCC患者中,174例(4.4%)达CR-mRECIST,97例(2.5%)同时达CR-RECISTv1.1。
- 总队列平均年龄65.9±9.8岁,男性85%,巴塞罗那临床肝癌C期70%,83%接受ICI为基础联合治疗,中位随访32.2个月(95%CI:29.9-34.4)。
主要发现
- 1年和3年总生存率分别为98%和86%。
- 仅CR-mRECIST和CR-RECISTv1.1患者的1年和3年无复发生存率分别为78%和55%、70%和42%。
- 因非复发原因停用ICI的患者中,首次mRECIST CR后接受免疫治疗≥6个月者无复发生存期长于更早停药者(p=0.008)。
- 9例接受根治性手术转化治疗的患者中,8例(89%)获病理学CR(CR-RECISTv1.1为2/2例;仅CR-mRECIST为6/7例)。
临床怎么用
- 作者认为,这些发现支持在免疫治疗背景下使用mRECIST进行临床决策。
- 作者认为,考虑停用ICI时,CR后继续治疗至少6个月似乎是可取的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)-based systemic therapies is unclear. APPROACH AND RESULTS: Retrospective study of patients with HCC who had CR according to modified Response Evaluation Criteria in Solid Tumors (CR-mRECIST) to ICI-based systemic therapies from 28 centers in Asia, Europe, and the United States. Of 3933 patients with HCC treated with ICI-based noncurative systemic therapies, 174 (4.4%) achieved CR-mRECIST, and 97 (2.5%) had CR according to RECISTv1.1 (CR-RECISTv1.1) as well. The mean age of the total cohort (male, 85%; Barcelona-Clinic Liver Cancer-C, 70%) was 65.9±9.8 years. The majority (83%) received ICI-based combination therapies. Median follow-up was 32.2 (95% CI: 29.9-34.4) months. One- and 3-year overall survival rates were 98% and 86%. One- and 3-year recurrence-free survival rates were excellent in patients with CR-mRECIST-only and CR-RECISTv1.1 (78% and 55%; 70% and 42%). Among patients who discontinued ICIs for reasons other than recurrence, those who received immunotherapy for ≥6 months after the first mRECIST CR had a longer recurrence-free survival than those who discontinued immunotherapy earlier ( p =0.008). Of 9 patients who underwent curative surgical conversion therapy, 8 (89%) had pathological CR (CR-RECISTv1.1, n= 2/2; CR-mRECIST-only, n= 6/7). CONCLUSIONS: Overall survival and recurrence-free survival of patients with CR-mRECIST-only and CR-RECISTv1.1 were excellent, and 6 of 7 patients with CR-mRECIST-only who underwent surgical conversion therapy had pathological CR. Despite potential limitations, these findings support the use of mRECIST in the context of immunotherapy for clinical decision-making. When considering ICI discontinuation, treatment for at least 6 months beyond CR seems advisable.
引用
- Scheiner B, Kang B, Balcar L, et al. Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy. Hepatology. 2024. PMID: 39643944. doi:10.1097/HEP.0000000000001163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。